Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, Tanner EJ, Fleming GF, Moroney JW, Pant A, Akasha AM, Davuluri RV, Kocherginsky M, Zhang B, Matei D. Chen S, et al. Among authors: kocherginsky m. J Clin Invest. 2022 Jul 15;132(14):e158800. doi: 10.1172/JCI158800. J Clin Invest. 2022. PMID: 35671108 Free PMC article. Clinical Trial.
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Gangadhar TC, et al. Among authors: kocherginsky m. Clin Cancer Res. 2011 Apr 1;17(7):1956-63. doi: 10.1158/1078-0432.CCR-10-2061. Epub 2011 Mar 29. Clin Cancer Res. 2011. PMID: 21447721 Free PMC article. Clinical Trial.
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Cohen EE, et al. Among authors: kocherginsky m. Clin Cancer Res. 2012 Sep 1;18(17):4785-93. doi: 10.1158/1078-0432.CCR-12-0110. Epub 2012 Aug 7. Clin Cancer Res. 2012. PMID: 22872575 Free PMC article. Clinical Trial.
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD. West DC, et al. Among authors: kocherginsky m. Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636357 Free PMC article.
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Cowan M, et al. Among authors: kocherginsky m. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. Gynecol Oncol. 2021. PMID: 34419285 Clinical Trial.
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.
Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, Schilder J, O'Shea KL, Kocherginsky M, Zhang B, Matei D. Barber EL, et al. Among authors: kocherginsky m. Cancer Res Commun. 2022 Oct;2(10):1293-1303. doi: 10.1158/2767-9764.crc-22-0147. Epub 2022 Oct 28. Cancer Res Commun. 2022. PMID: 36388466 Free PMC article. Clinical Trial.
171 results